A - Research and Development

SOLICITATIONS - November 9, 2001

• ENHANCED HFN MATERIALS
  Naval Surface Warfare Center, Carderock Division, 9500 MacArthur Blvd., West Bethesda, MD 20817-5700 (SOL N0016702Q0041)
• 120MM ANTI-PERSONNEL CANISTER CARTRIDGE
  US Army ARDEC, AMSTA-AR-PC, Picatinny Arsenal, New Jersey 07806-5000 (SOL DAAE30-02-R-0602)
• FLAME RESISTANT COVERALLS
  Department of the Navy, Naval Supply Systems Command, FISC PUGET SOUND, 467 W STREET, BREMERTON, WA, 98314-5000 (SOL N00406-02-T-0285)
• 120MM ANTI-PERSONNEL CANISTER CARTRIDGE
  US Army ARDEC, AMSTA-AR-PC, Picatinny Arsenal, New Jersey 07806-5000 (SOL DAAE30-01-R-0607)
• A -- INTELLIGENCE FUSION FOR TARGETS-UNDER-TREES (PART 1 OF 2)
  Department of the Air Force, Air Force Materiel Command, AFRL -- Rome Research Site, AFRL/Information Directorate 26 Electronic Parkway, Rome, NY, 13441-4514 (SOL Reference-Number-PRDA-02-02-IFKPA)
• INTELLIGENT COMBAT OUTPOST RAPTOR
  US Army ARDEC, AMSTA-AR-PC, Picatinny Arsenal, New Jersey 07806-5000 (SOL DAAE30-02-Q-0104)
• EFFECTIVE, AFFORDABLE, REUSABLE SPEECH-TO-TEXT (EARS)
  Other Defense Agencies, Defense Advanced Research Projects Agency, Contracts Management Office, 3701 North Fairfax Drive, Arlington, VA, 22203-1714 (SOL BAA02-06)
• NEW THERAPEUTIC TARGETS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASE -SYNTHESIS OF LEAD COMPOUNDS
  National Institutes of Health, Division of Research Acquisition, OLAO/OA/OD, 6100 Executive Blvd., MSC 7540, Room 6E01, Bethesda, Maryland 20892-7540 (SOL 260-02-03)
• NEW THERAPEUTIC TARGETS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASE -- PRECLINICAL TOXICOLOGY
  National Institutes of Health, Division of Research Acquisition, OLAO/OA/OD, 6100 Executive Blvd., MSC 7540, Room 6E01, Bethesda, Maryland 20892-7540 (SOL 260-02-02)
• NEW THERAPEUTIC TARGETS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASE -- PHARMACEUTICAL FORMULATION OF DRUGS FOR CLINICAL STUDY
  National Institutes of Health, Division of Research Acquisition, OLAO/OA/OD, 6100 Executive Blvd., MSC 7540, Room 6E01, Bethesda, Maryland 20892-7540 (SOL 260-02-04)
• NEW THERAPEUTIC TARGETS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASE -- SYNTHESIS OF BULK CHEMICALS AND DRUGS FOR PRECLINICAL AND CLINICAL STUDIES
  National Institutes of Health, Division of Research Acquisition, OLAO/OA/OD, 6100 Executive Blvd., MSC 7540, Room 6E01, Bethesda, Maryland 20892-7540 (SOL 260-02-05)
• ADVANCED ENERGETICS AND NOVEL EXPLOSIVES
  Defense Threat Reduction Agency (AM), DTRA Annex, 8725 John J. Kingman Road, MSC 6201, Fort Belvoir, VA 22060-6201 (SOL TDS029971764)
• NGST -- SPACECRAFT SINGLE BOARD COMPUTER
  NASA/Goddard Space Flight Center, Code 214.1, Greenbelt, MD 20771 (SOL 2141-360-001)